profit from every $100 of sales.
$0$100
PTC Therapeutics
$63.49+0.21% today
-15.3% in 1 year
1-year low $59.241-year high $89.55
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $7.77 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What PTC Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $699 million in 2022 to $1.73 billion in 2025, with $683 million of profit last year.
SalesProfit
PTC Therapeutics vs. similar companies
PTC Therapeutics grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| PTC Therapeutics | 7.8× · Cheap | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads PTC Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 381 | 539 | 699 | 938 | 807 | 1,731 | |
| – | – | 654 | 872 | 749 | 1,684 | |
| -432 | -374 | -440 | -349 | -147 | 857 | |
| -388 | -310 | -368 | -330 | -120 | 888 | |
| -438 | -524 | -559 | -627 | -363 | 683 | |
| -6.64 | -7.43 | -7.79 | -8.37 | -4.73 | 7.78 | |
| – | – | 93.6% | 93.0% | 92.9% | 97.3% | |
| -113.4% | -69.5% | -63.0% | -37.3% | -18.2% | 49.5% | |
| -115.1% | -97.3% | -80.0% | -66.8% | -45.0% | 39.4% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 2,208 | 1,938 | 1,706 | 1,896 | 1,705 | 2,899 |
| Cash | 209 | 190 | 280 | 594 | 780 | 985 |
| Total debt | – | – | 1,462 | 2,229 | 2,471 | 2,707 |
| Total liabilities | 1,726 | 1,937 | 2,053 | 2,714 | 2,803 | 3,104 |
| 482 | 1 | -347 | -819 | -1,098 | -205 | |
| 66 | 70 | 72 | 75 | 77 | 88 | |
| -70.8% | -20,570.9% | -35.2% | -31.8% | -11.3% | 26.8% | |
| -90.9% | -36,432.6% | 161.1% | 76.6% | 33.1% | -332.5% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -194 | -251 | -357 | -158 | -108 | 711 | |
| – | – | 152 | 121 | 74 | 300 | |
| – | – | -509 | -279 | -182 | 411 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | – | – | – | – | |
| 70 | 104 | 110 | 131 | 75 | 75 |
Valuation
- 7.8×
- –
- –
- -31.8×
- 3.1×
- 12.9×
- 7.9×
- 7.8%
- 12.9%
- 0.0%
Profitability
- 97.3%
- 49.5%
- 39.4%
- -2.7%
- -2.4%
- 15.1%
- 99.8%
- -6.5%
- -3.5%
- 54.1%
Growth
- +35.4%
- –
- +486.0%
- –
- +3.1%
Financial health
- 19.8×
- -2.19
- 13.8%
- -1.0×
- 2.44
- 2.36
- 0.29
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 34%of 946
Top 2%of 871
Top 7%of 563
Top 17%of 867
Top 10%of 986
What analysts expect
- Average price target
- $89.67
- Range
- $50.00 – $120.00
- 5 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.03 | -0.45 | +93.3% |
| Feb 19, 2026 | -1.67 | -0.21 | −695.2% |
| Nov 4, 2025 | 0.20 | -1.19 | +116.8% |
| Aug 7, 2025 | -0.83 | -1.07 | +22.4% |
| May 6, 2025 | 10.04 | -1.08 | +1,029.6% |
| Feb 27, 2025 | -0.24 | -1.12 | +78.6% |
| Nov 7, 2024 | -1.39 | -1.54 | +9.7% |
| Aug 8, 2024 | -1.16 | -1.00 | −16.0% |
News
Atrium Therapeutics, Inc. reports Q3 resultsSeeking Alpha · Nov 13, 2026Cullinan Therapeutics reports Q3 resultsSeeking Alpha · Nov 10, 2026Enliven Therapeutics GAAP EPS of -$0.36Seeking Alpha · Nov 6, 2026Cognition Therapeutics, Inc. Q3 2026 Earnings Call SummaryYahoo Finance · Nov 5, 2026Kymera Therapeutics, Inc. Q3 2026 Earnings Call SummaryYahoo Finance · Oct 29, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
6/7Passes 6 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
63Pass
Benjamin Graham
75Pass
Philip Fisher
80Pass
Peter Lynch
100Pass
Joel Greenblatt
58No pass
Charlie Munger
63Pass
Terry Smith
67Pass
Questions about PTC Therapeutics
Is PTC Therapeutics a good stock to buy?
A business with weak numbers, and the price looks low. 6 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the PTC Therapeutics AI analysis
What does PTC Therapeutics do?
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. It is in Biotechnology, based in Warren, NJ, United States, with 991 employees.
Does PTC Therapeutics pay a dividend?
No. PTC Therapeutics does not pay a dividend at the moment.
Is PTC Therapeutics stock halal?
No. PTC Therapeutics does not pass our halal screen: its debt is 51% of its market value, at or above the 33% limit. How we check
How has PTC Therapeutics stock done over the past year?
Down 15.3% over the past twelve months, to $63.49. It traded between $59.24 and $89.55 and is 29.1% below its high.
Who are PTC Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with PTC Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.